Wu, Yutuan
Jennings, Nicholas B.
Sun, Yunjie
Dasari, Santosh K.
Bayraktar, Emine
Corvigno, Sara
Stur, Elaine
Glassman, Deanna
Mangala, Lingegowda S.
Lankenau Ahumada, Adrian
Westin, Shannon N.
Sood, Anil K. http://orcid.org/0000-0003-4242-1762
Hu, Wei
Funding for this research was provided by:
National Institutes of Health (P50CA217685-02, P50CA217685-02)
U.S. Department of Defense (OC180136)
Ovarian Cancer Research Alliance (FP00006137)
Article History
Received: 6 November 2021
Accepted: 11 December 2021
First Online: 30 January 2022
Declarations
:
: AKS reports consulting for KIYATEC, Merck, and Astra Zeneca; being a stockholder in Bio-Path Holdings; and receiving research funding from MTrap. WH reports research funding from Geistlich Pharma AG. YW reports receiving scholarship to study abroad from the China Scholarship Council (CSC No. 201906100162). SNW reports consulting (Agenus, AstraZeneca, Clovis Oncology, Eisai, EQRX, GSK, Lily, Mereo, Immunogen, Roche/Genentech, Novartis, Merck, Pfizer, Zentalis) and research funding (AstraZeneca, Bio-Path, Clovis Oncology, OncXema, GSK, Roche/Genentech, Bayer, Cotinga Pharmaceuticals, Inc., Mereo, Novartis, Zentalis). The remaining authors declare no competing interests.